[Autoinflammatory syndromes and AA amyloidosis]

Area of Science:

• Rheumatology
• Genetics
• Nephrology

Background:

• Autoinflammatory syndromes (AIS) are a group of rare genetic disorders characterized by recurrent, unprovoked inflammatory attacks, often accompanied by fever, rash, and serositis.
• Elevated inflammatory markers like C-reactive protein (CRP) and serum amyloid A (SAA) are typical during acute episodes.
• Systemic AA amyloidosis is a serious complication of chronic inflammation, primarily affecting the kidneys.

Purpose of the Study:

• To summarize the clinical presentation, diagnosis, and management of autoinflammatory syndromes.
• To highlight the pathogenesis and clinical implications of secondary AA amyloidosis in the context of AIS.
• To emphasize the importance of early detection and treatment to preserve organ function.

Main Methods:

• Review of clinical characteristics and diagnostic approaches for AIS.
• Discussion of current therapeutic strategies, including colchicine and biologic agents.
• Analysis of the development and management of AA amyloidosis secondary to chronic inflammation.

Main Results:

• AIS diagnosis relies on clinical patterns, family history, and molecular genetic testing.
• Colchicine is effective for familial Mediterranean fever but not all AIS; anakinra and canakinumab are options for refractory cases.
• Early identification and treatment of AA amyloidosis, particularly proteinuria, can preserve renal function and prevent dialysis.

Conclusions:

• Prompt diagnosis and targeted therapy are essential for managing AIS and mitigating inflammatory exacerbations.
• Effective management of underlying chronic inflammation is critical to prevent the development or progression of AA amyloidosis.
• Timely intervention in AA amyloidosis can preserve organ function, especially renal health, and improve long-term patient outcomes.